Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining with an anti-PD 1 or PDL-1 agent.
The company’s track record has been strong, with the company beating estimates in each of the last four quarters, with an average positive earnings surprise of 8.91%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the first quarter of 2018. While our consensus called for a loss of 54 cents per share, the company reported a loss of 49 cents.
Revenues: In the first quarter of 2018, the company did not recognize any collaboration revenues. However, the Zacks Consensus Estimate for the metric stood at $0.75 million for the reported period.
Pipeline Update: The company completed enrollment in expansion cohort of a phase II study evaluating its lead candidate, tazemetostat in combination with prednisolone, being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Enrollment is also completed in a phase Ib study evaluating tazemetostat in combination with Roche’s Tecentriq in patinets with r/r DLBCL. Tazemetostat was granted orphan drug designation for the treatment of DLBCL and malignant mesothelioma in Europe.
Share Price Impact: The shares were inactive in pre-market trading.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Image: Bigstock
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining with an anti-PD 1 or PDL-1 agent.
The company’s track record has been strong, with the company beating estimates in each of the last four quarters, with an average positive earnings surprise of 8.91%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the first quarter of 2018. While our consensus called for a loss of 54 cents per share, the company reported a loss of 49 cents.
Revenues: In the first quarter of 2018, the company did not recognize any collaboration revenues. However, the Zacks Consensus Estimate for the metric stood at $0.75 million for the reported period.
Pipeline Update: The company completed enrollment in expansion cohort of a phase II study evaluating its lead candidate, tazemetostat in combination with prednisolone, being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Enrollment is also completed in a phase Ib study evaluating tazemetostat in combination with Roche’s Tecentriq in patinets with r/r DLBCL. Tazemetostat was granted orphan drug designation for the treatment of DLBCL and malignant mesothelioma in Europe.
Share Price Impact: The shares were inactive in pre-market trading.
Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise | Epizyme, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>